Growth & profitability
- Revenue has grown 194.9% per year over the past 5 years.
- Operating margin has expanded, at -14.1% in the latest year.
Financial health
- Total debt has grown slower than revenue (57.0% vs 194.9% per year).
FENC Financials FENNEC PHARMACEUTICALS INC.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $45M | -$9.7B | 0.0% | -14.1% | — | — | $37M |
| 2024 | $48M | -$436M | 0.0% | 5.4% | — | $19M | $27M |
| 2023 | $21M | -$16.0B | 94.1% | -60.1% | — | $31M | $13M |
| 2022 | $2M | -$24M | 94.4% | -1471.6% | — | $25M | $24M |
| 2021 | — | -$17M | — | — | — | $5M | $21M |
| 2020 | $200000 | -$18M | 0.0% | -8942.5% | — | — | $30M |
| 2019 | $0 | -$13M | — | — | — | — | $14M |
| 2018 | $0 | -$10M | — | — | — | — | $23M |
| 2017 | $0 | -$7M | — | — | — | — | $28M |
| 2016 | $0 | -$3M | — | — | — | — | $4M |
| 2015 | $0 | -$659000 | — | — | — | — | $942000 |
| 2014 | $0 | -$2M | — | — | — | — | $2M |
| 2014 | $0 | -$111M | — | — | -$90M | — | $593000 |
| 2014 | $0 | -$111M | — | — | -$89M | — | $1M |
| 2014 | $0 | -$110M | — | — | -$89M | — | $1M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $15M | $201000 | 0.0% | -0.8% | — | — | $40M |
| Dec '25 | $14M | -$5M | 0.0% | -18.5% | — | — | $37M |
| Sep '25 | $12M | -$638000 | 0.0% | -1.5% | — | $19M | $22M |
| Jun '25 | $10M | -$3M | 0.0% | -28.3% | — | $19M | $19M |
| Mar '25 | $9M | -$1M | 0.0% | -9.2% | — | $19M | $23M |
| Dec '24 | $8M | -$2M | 0.0% | -11.8% | — | $19M | $27M |
| Sep '24 | $7M | -$6M | 0.0% | -74.6% | — | $32M | $40M |
| Jun '24 | $7M | -$6M | 0.0% | -69.4% | — | $32M | $43M |
| Mar '24 | $25M | $13M | 0.0% | 54.2% | — | $31M | $51M |
| Dec '23 | $10M | -$3M | 93.0% | -18.7% | — | $31M | $13M |
| Sep '23 | $7M | -$2M | 94.9% | -15.6% | — | $26M | $12M |
| Jun '23 | $3M | -$5M | 95.5% | -140.3% | — | $25M | $15M |
| Mar '23 | $2M | -$6M | 94.3% | -314.3% | — | $25M | $18M |
| Dec '22 | — | -$7M | — | — | — | $25M | $24M |
| Sep '22 | — | -$8M | — | — | — | $25M | $30M |
| Jun '22 | — | -$5M | — | — | — | $5M | $15M |
| Mar '22 | — | -$4M | — | — | — | $5M | $18M |
| Dec '21 | — | -$4M | — | — | — | $5M | $21M |
| Sep '21 | — | -$4M | — | — | — | — | $24M |
| Jun '21 | — | -$4M | — | — | — | — | $27M |
Valuation over time
How the market has priced FENC against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 154.9× (Mar '23) to 6.8× (Jun '26).
P/S
Frequently asked questions
Is FENC growing its revenue and profit?
Over the past 5 years, FENNEC PHARMACEUTICALS INC.'s revenue has grown 194.9% per year. These are computed facts, not advice.
How much debt does FENC have?
As of FY2025, FENNEC PHARMACEUTICALS INC. reported — of total debt against $37M of cash.
What is FENC's profit margin?
In FY2025, gross margin was —, operating margin -14.1%, and net margin -21820.3%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.